- Phlow Corp. welcomed a US$15.97 million investment from the U.S. Economic Development Administration to launch the End-to-End Commercialization Project led by Civica, Inc.
- As a founding member of the Alliance for Building Better Medicine, Phlow will contribute domestic API development and manufacturing expertise to support a U.S.-based pharmaceutical commercialization pathway.
Phlow Corp. has welcomed the Alliance for Building Better Medicine’s announcement of a US$15.97 million investment from the U.S. Economic Development Administration (EDA) to launch the End-to-End Commercialization Project, led by Civica, Inc. The initiative is part of Virginia’s Advanced Pharmaceutical Manufacturing Tech Hub and aims to establish a domestic pathway spanning key starting materials, active pharmaceutical ingredient (API) manufacturing, finished dose formulation and manufacturing, regulatory approval, and delivery of medicines to patients.
As a founding member of the Alliance for Building Better Medicine, the CDMO will provide expertise in domestic API development and contract manufacturing alongside Civica, Occam Systems, and more than 55 public and private partners. The collaboration is intended to strengthen the U.S. pharmaceutical manufacturing ecosystem.
The End-to-End Commercialization Project will initially focus on four essential sterile injectable medicines used in emergency, anesthesia, and critical care settings. According to the announcement, the project will connect domestically sourced key starting materials with API manufacturing, finished dose production, regulatory approval, and commercialization through a coordinated national ecosystem.
“Today’s announcement demonstrates how partners across industry, government, academia, and nonprofit organizations can work together to strengthen domestic pharmaceutical manufacturing and build a more resilient medicine supply chain.”
Phlow Chief of Staff and Founding Board Chair of the Alliance for Building Better Medicine, Robby Demeria
The company said the project builds on public-private collaboration that has helped establish Virginia as a hub for advanced pharmaceutical manufacturing. Phlow added that the initiative is intended to strengthen supply chain resilience, support national preparedness, and expand the country’s domestic pharmaceutical development, commercialization, and manufacturing capabilities.
